ATAkihiro Tanaka

Akihiro Tanaka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Akihiro Tanaka has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comparative effectiveness and safety of five Janus kinase inhibitors in real-world clinical practice: the multicentre ANSWER cohort

    by Yuki Etani, Yasutaka Okita, Kohei Tsujimoto, Yuichi Maeda, So Kuroda, Takaaki Noguchi, Takayuki Fujii, Akira Onishi, Tadashi Okano, Motomu Hashimoto, et al.

    Objectives: To compare treatment effectiveness and safety among five Janus kinase inhibitors (JAKi) in patients with RA and to identify factors associated with treatment discontinuation in real-world clinical practice. Methods: This retrospective multicentre study used data from the ANSWER (Kansai Consortium for Well-being of Rheumatic Disease Patients) cohort in Japan. RA treatment courses initiating tofacitinib, baricitinib, peficitinib, upadacitinib or filgotinib between 2013 and 2025 were included. Treatment discontinuation due to ineffectiveness and adverse events was evaluated using Kaplan–Meier analysis and multivariable Cox proportional hazards models with multiple imputation. Analyses were adjusted for patient, disease and treatment characteristics, including prior treatment history. Results: A total of 1798 treatment courses from 1240 patients were analysed. Discontinuation risk due to ineffectiveness was lower with upadacitinib [hazard ratio (HR) 0.33, 95% CI 0.24–0.47] and filgotinib (HR 0.59, 95% CI 0.42–0.85) than with tofacitinib (reference), baricitinib (HR 0.82, 95% CI 0.63–1.06) and peficitinib (HR 1.23, 95% CI 0.89–1.70). Differences in discontinuation due to adverse events were observed only between upadacitinib (HR 0.57, 95% CI 0.38–0.85) and peficitinib (reference). Prior IL-6i or JAKi use increased ineffectiveness-related discontinuation for tofacitinib, baricitinib and peficitinib, but not upadacitinib (IL-6i/JAKi: HR 0.67/1.14, 95% CI 0.38–1.16/0.65–1.98) or filgotinib (HR 0.83/1.38, 95% CI 0.45–1.53/0.72–2.65). Conclusion: Treatment effectiveness and safety differed among JAKi in real-world clinical practice. Upadacitinib and filgotinib were associated with higher treatment persistence, and the adverse impact of prior IL-6i or JAKi exposure was not evident for these agents.

  • Open Access

    The Correlation between the Vascular Calcification Score of the Coronary Artery and the Abdominal Aorta in Patients with Psoriasis

    by Trang Nguyen-Mai Huynh, Fumikazu Yamazaki, Izumi Kishimoto, Akihiro Tanaka, Yonsu Son, Yoshio Ozaki, Kazuya Takehana, Hideaki Tanizaki

    Psoriasis is known as an independent risk factor for cardiovascular disease due to its chronic inflammation. Studies have been conducted to evaluate the progress of atherosclerotic plaques in psoriasis. However, inadequate efforts have been made to clarify the relationship between atherosclerosis progress in coronary arteries and other important blood vessels. For that reason, we investigated the correlation and development of the coronary artery calcification score (CACS) and the abdominal aortic calcification score (AACS) during a follow-up examination. Eighty-three patients with psoriasis underwent coronary computed tomography angiography (CCTA) for total CACS and abdominal computed tomography (AbCT) for total AACS. PASI score, other clinical features, and blood samples were collected at the same time. The patients’ medical histories were also retrieved for further analysis. Linear regression was used to analyze the CACS and AACS associations. There was a moderate correlation between CACS and AACS, while both calcification scores relatively reflected the coronary plaque number, coronary stenosis number, and stenosis severity observed with CCTA. Both calcification scores were independent of the PASI score. However, a significantly higher CACS was found in psoriatic arthritis, whereas no similar phenomenon was recorded for AACS. To conclude, both CACS and AACS might be potential alternative tests to predict the presence of coronary lesions as confirmed by CCTA.


  • Open Access

    Relationship between Psoriasis and Prevalence of Cardiovascular Disease in 88 Japanese Patients

    by Fumikazu Yamazaki, Kazuya Takehana, Akihiro Tanaka, Yonsu Son, Yoshio Ozaki, Hideaki Tanizaki

    Psoriasis is a systemic inflammatory disease known to affect survival in the presence of cerebral or cardiovascular comorbidities. However, no clear guidelines have been defined regarding the extent of vascular lesion testing that should be performed in patients with psoriasis. We therefore performed coronary computed tomography angiography (CCTA) in 88 Japanese patients with psoriasis who visited Kansai Medical University Hospital between 2015 and 2019 and determined the ankle–brachial pressure index (ABI) for 44 of these patients. CCTA abnormalities were found in 39 of the 88 patients, and a need for treatment was identified in 14 patients. The prevalence of cardiovascular lesions in these patients was 15.9%, significantly higher than that in the healthy Japanese population (6.38% according to the Suita Study). In the 44 patients with results for both ABI and CCTA, the rates of CCTA vascular lesions were significantly higher in cases with ABIs indicating hard vessels or above than in cases with supple, normal, or slightly stiff vessels. This is the first report to show a correlation between CCTA and ABI in psoriasis patients. ABI was considered useful as a preliminary test before CCTA. The univariate analysis of the abnormal and normal CCTA groups showed that the prevalence differed significantly among patients with psoriatic arthritis, erythrodermic psoriasis, older age, pre-existing conditions, drinking, and hypertension. The multivariate analysis showed correlations with arthritic or erythrodermic psoriasis.


  • Open Access

    Immunomodulatory drugs suppress Th1-inducing ability of dendritic cells but enhance Th2-mediated allergic responses

    by Vien Phan, Tomoki Ito, Muneo Inaba, Yoshiko Azuma, Kayoko Kibata, Noriko Inagaki-Katashiba, Akihiro Tanaka, Atsushi Satake, Shosaku Nomura

    Immunomodulatory drugs (IMiDs), lenalidomide and pomalidomide, are widely used treatments for multiple myeloma; however, they occasionally lead to episodes of itchy skin and rashes. Here, we analyzed the effects of IMiDs on human myeloid dendritic cells (mDCs) as major regulators of Th1 or Th2 responses and the role they play in allergy. We found that lenalidomide and pomalidomide used at clinical concentrations did not affect the survival or CD86 and OX40-ligand expression of blood mDCs in response to lipopolysaccharide (LPS) and thymic stromal lymphopoietin (TSLP) stimulation. Both lenalidomide and pomalidomide dose-dependently inhibited interleukin-12 (IL-12) and TNF production and STAT4 expression, and enhanced IL-10 production in response to LPS. When stimulated with TSLP, both IMiDs significantly enhanced CCL17 production and STAT6 and IRF4 expression and promoted memory Th2-cell responses. In 46 myeloma patients, serum CCL17 levels at the onset of lenalidomide-associated rash were significantly higher than those without rashes during lenalidomide treatment and those before treatment. Furthermore, serum CCL17 levels in patients who achieved a very good partial response (VGPR) were significantly higher compared with a less than VGPR during lenalidomide treatment. The median time to next treatment was significantly longer in lenalidomide-treated patients with rashes than those without. Collectively, IMiDs suppressed the Th1-inducing capacity of DCs, instead promoting a Th2 response. Thus, the lenalidomide-associated rashes might be a result of an allergic response driven by Th2-axis activation. Our findings suggest clinical efficacy and rashes as a side effect of IMiDs are inextricably linked through immunostimulation.


  • Serum high-mobility group box 1 is correlated with interferon-α and may predict disease activity in patients with systemic lupus erythematosus

    by A Tanaka, T Ito, K Kibata, N Inagaki-Katashiba, H Amuro, T Nishizawa, Y Son, Y Ozaki, S Nomura

    Sensing self-nucleic acids through toll-like receptors in plasmacytoid dendritic cells (pDCs), and the dysregulated type I IFN production, represent pathogenic events in the development of the autoimmune responses in systemic lupus erythematosus (SLE). Production of high-mobility group box-1 protein (HMGB1) promotes type I IFN response in pDCs. To better understand the active pathogenic mechanism of SLE, we measured serum levels of HMGB1, thrombomodulin, and cytokines (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17A, IL-17F, IFNα, IFNγ, TNFα) in 35 patients with SLE. Serum HMGB1 and IFNα were significantly higher in patients with active SLE (SLE Disease Activity Index (SLEDAI) score ≥ 6) compared with healthy donors or patients with inactive SLE. Furthermore, the HMGB1 levels were significantly correlated with IFNα levels. By qualitative analysis, the detection of serum IFNα or HMGB1 suggests active SLE and the presence of SLE-related arthritis, fever, and urinary abnormality out of SLEDAI manifestations. Collectively, HMGB1 and IFNα levels are biomarkers reflecting disease activity, and qualitative analysis of IFNα or HMGB1 is a useful screening test to estimate SLE severity and manifestations. Our results suggest the clinical significance of type I IFNs and HMGB1 as key molecules promoting the autoimmune process in SLE.


  • Open Access

    The immunomodulatory-drug, lenalidomide, sustains and enhances interferon-α production by human plasmacytoid dendritic cells

    by Kayoko Kibata, Tomoki Ito, Muneo Inaba, Akihiro Tanaka, Ryoichi Iwata, Noriko Inagaki-Katashiba, Vien Phan, Atsushi Satake, Shosaku Nomura

    Background: Lenalidomide (LEN), an immunomodulatory drug (IMiD), is currently used for treatment of multiple myeloma (MM). LEN potentiates T cell and natural killer cell functions. However, the cellular and molecular mechanisms underlying the immunomodulatory effects of LEN remain unclear. We focused on the effects of LEN on human plasmacytoid dendritic cells (pDCs), which are the major source of interferon (IFN)-α in the blood and play a central role in innate immune responses. Results: We found that bortezomib, a proteasome inhibitor used to treat MM, killed pDCs but that 0.1–3 μM LEN (covering clinical plasma concentration range) did not affect pDC survival or CD86 expression. Bortezomib inhibited pDC-derived IFN-α production in a dose-dependent fashion, but 0.1–3 μM LEN sustained pDC-derived IFN-α production when stimulated with an optimal concentration of CpG-ODN 2216 (3 μM). In pDCs stimulated with a low concentration of CpG-ODN (0.1 μM), LEN enhanced IFN-α production. These results indicated that LEN, when used at a clinically relevant concentration, can potentially enhance IFN-α production by pDCs. Conclusion: Collectively, our findings unveiled a novel target of LEN and extend the repertoire of the drug’s known immunomodulatory effects. These effects may explain the low incidence of herpes zoster viral infection observed during LEN treatment compared with bortezomib treatment. LEN may function as an IMiD affecting a wide array of immune cells, including pDCs, leading to amplification of a positive immune axis able to eliminate MM cells.


  • Open Access

    Combined use of ursodeoxycholic acid and bosentan prevents liver toxicity caused by endothelin receptor antagonist bosentan monotherapy: two case reports

    by Tomoki Ito, Yoshio Ozaki, Yonsu Son, Tohru Nishizawa, Hideki Amuro, Akihiro Tanaka, Takeshi Tamaki, Shosaku Nomura

    Pulmonary arterial hypertension is a fatal disease characterized by progressive remodeling of the pulmonary arteries and an increase in pulmonary vascular resistance. Up to 50% of patients with systemic sclerosis have pulmonary arterial hypertension, which significantly affects the prognosis. The endothelin receptor antagonist bosentan is used for the treatment of pulmonary arterial hypertension and shows a great beneficial effect. However, the most frequent side effect of bosentan is liver toxicity, which often requires dose reduction and discontinuation. We report two cases (a 64-year-old Japanese woman and a 69-year old Japanese woman) of systemic sclerosis, both with severe Raynaud’s phenomenon and pulmonary arterial hypertension. Both patients had initially received bosentan monotherapy, which caused liver toxicity as indicated by increased levels of alanine aminotransferase, alkaline phosphatase, and gamma-glutamyltransferase. After dose reduction or discontinuation of bosentan, these liver function abnormalities were normalized and the patients subsequently received retreatment with a combination of bosentan and ursodeoxycholic acid. The results of liver function tests did not show any abnormalities after this combination therapy. These reports suggest the usefulness of ursodeoxycholic acid for preventing liver toxicity caused by bosentan. Thus, the addition of ursodeoxycholic acid to the treatment protocol is expected to be useful when liver toxicity emerges as a side effect of bosentan.


  • Alterations of Renal Vasopressin V1A and V2 Receptors in Spontaneously Hypertensive Rats

    by Atsuo Tahara, Junko Tsukada, Yuichi Tomura, Koh-Ichi Wada, Toshiyuki Kusayama, Noe Ishii, Takeyuki Yatsu, Wataru Uchida, Nobuaki Taniguchi, Akihiro Tanaka

    To elucidate the role of arginine vasopressin (AVP) in a hypertensive state, the characteristics of renal cortex V1A and medulla V2 receptors in young spontaneously hypertensive rats (SHR) during the developmental phase of hypertension were compared with those of age-matched Wistar-Kyoto (WKY) rats using the radioligand receptor assay technique. The systolic blood pressure of 8-week-old SHR was statistically significantly higher than that of WKY rats (142 ± 1 vs. 125 ± 2 mm Hg). The plasma AVP levels were also significantly higher in SHR than in WKY rats (3.20 ± 0.41 vs. 1.96 ± 0.34 pg/ml). In SHR, the maximum capacity of 3H-d(CH2)5Tyr(Me)AVP binding to cortical V1A receptors (Bmax) was statistically significantly higher than that of WKY rats (39.7 ± 2.7 vs. 22.4 ± 0.9 fmol/mg protein). Furthermore, the Bmax values of 3H-AVP binding to medullary V2 receptors in SHR were also significantly higher than in WKY rats (40.2 ± 1.9 vs. 28.3 ± 1.3 fmol/mg protein). However, the apparent dissociation constant (Kd) values of renal cortex V1A and medulla V2 receptors in SHR and WKY rats were not significantly different. These results indicate that increased amounts of renal cortex V1A and medulla V2 receptors in SHR play an important role in the pathophysiology of hypertension.